Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Follow-Up Questions
Sana Biotechnology Inc のCEOは誰ですか？
Mr. Steven Harr は Sana Biotechnology Inc の President で、2018 から在籍しています。
SANA の株価パフォーマンスは？
SANA の現在の価格は $5.53 で、最終取引日から 1.01% decreased 変動しました。
Sana Biotechnology Inc の主な事業テーマや業界は？
Sana Biotechnology Inc は Biotechnology 業界、セクターは Health Care に属しています。
